Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-08
2008-01-08
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263220, C514S263340, C544S267000, C544S269000, C544S270000, C544S271000, C544S272000
Reexamination Certificate
active
11189202
ABSTRACT:
Disclosed are novel A2Badenosine receptor antagonists having the structure of Formula I or Formula IIThe compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
REFERENCES:
patent: 5776940 (1998-07-01), Daluge et al.
patent: 6825349 (2004-11-01), Kalla et al.
patent: 6977330 (2005-12-01), Santa Cruz et al.
patent: 2003/0207879 (2003-11-01), Baraldi et al.
Profire, Farmacia 1997 45(6) 55-68.
Mazur, Farmatsevtichnii Zh. 1996 (3) 82-84.
Priimenko, Ukrainskii Khimicheskii Zh. 62(7-8) 121-124.
Klosa, Arch. Pharm. 1956 287, 211-217.
Elzein Elfatih
Ibrahim Prabha
Kalla Rao
Li Xiaofen
Palle Venkata
Berch Mark L.
CV Therapeutics Inc.
CV Therapeutics, Inc.
Hartrum J. Elin
LandOfFree
A 2B adenosine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with A 2B adenosine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A 2B adenosine receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3936791